NovelStem International Corp.

NovelStem International Corp. operates as a holding company focused on biotechnology assets. The company previously held an equity stake in NewStem Ltd, a development-stage Israeli biotech company specializing in human pluripotent stem cells for oncology drug discovery and cancer diagnostics. Following NewStem’s liquidation and the sale of its interest in the NetCo joint venture, NovelStem’s primary asset consists of rights to future licensing proceeds and profits from proprietary stem cell technology relicensed by Yissum Research Development Company. Potential customers for this technology comprise healthcare institutions, oncologists, and pharmaceutical licensees.

The company operates without direct employees, relying on consultants to carry out its administrative and management functions. NovelStem maintains its principal executive offices in Parkland, Florida, and conducts its business activities in the United States while retaining economic exposure to biotechnology rights originally developed in Israel.

Summary of the business section of NovelStem International's latest annual report, written by StockData.

“Company has in place a finance agreement with two individuals who are shareholders and directors under which it borrowed $ 750,000 and an additional finance agreement with a shareholder under which it borrowed $ 300,000 for working capital needs (see Note 4).”